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Apolipoprotein C IIIone of the most important post-translational modiﬁcations. Defects in the glycan
biosynthesis result in congenital malformation syndromes, also known as congenital disorders of
glycosylation (CDG). Based on the iso-electric focusing patterns of plasma transferrin and apolipoprotein
C-III a combined defect in N- and O-glycosylation was identiﬁed in patients with autosomal recessive cutis
laxa type II (ARCL II). Disease-causing mutations were identiﬁed in the ATP6V0A2 gene, encoding the a2
subunit of the vacuolar H+-ATPase (V-ATPase). The V-ATPases are multi-subunit, ATP-dependent proton
pumps located in membranes of cells and organels. In this article, we describe the structure, function and
regulation of the V-ATPase and the phenotypes currently known to result from V-ATPase mutations. A
clinical overview of cutis laxa syndromes is presented with a focus on ARCL II. Finally, the relationship
between ATP6V0A2 mutations, the glycosylation defect and the ARCLII phenotype is discussed.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionDetailed clinical and laboratory characterization of autosomal
recessive cutis laxa phenotypes has revealed a surprising connection
between glycosylation defects and cutis laxa. The discovery of
mutations in the ATP6V0A2 gene, encoding the a2 subunit of the
vacuolar H+-ATPase (V-ATPase), in autosomal recessive cutis laxa
type II (ARCL II) furthermore highlighted the crucial role of the V-
ATPase in glycosylation processes within the Golgi [1]. In this article,
we will review the current knowledge of V-ATPase complex
composition, its function and regulation. Known diseases associated
with V-ATPase malfunction will be described with a special focus on
ARCL II. Finally, we will discuss the possible links between a2
dysfunction, aberrant glycosylation and the disease pathophysiology.
2. Vacuolar H+-ATPases
Vacuolar H+-ATPases are ATP-dependent proton pumps composed
of twomulti-subunit domains, V1 and V0, containing eight (A through
H, total of 640 kDa) and ﬁve different subunits (a, c, c″, d and e in
mammals, total of 260 kDa), respectively. The structural organization
of the V-ATPase complex is shown in Fig. 1. The cytoplasmic V1
domain carries out ATP hydrolysis whereas the V0 domain, embeddedll rights reserved.in the plasma or organel membrane, is responsible for transfer of
protons across the membrane into vesicles or into the extracellular
space. As shown in Fig. 1, the two domains are connected by a central
and two peripheral stalks, which couple ATP hydrolysis to proton
translocation through a rotary mechanism similar to the mitochon-
drial F-ATPase complex [2,3]. The detailed mechanism through which
these processes are coupled has already been described extensively
and will therefore not be repeated here [4–6].
V-ATPases were originally described as intracellular membrane
proteins, present in endosomes, lysosomes, Golgi-derived vesicles,
clathrin-coated vesicles and secretory vesicles. However, they have
also been identiﬁed at the surface of a variety of cell types such as
renal intercalated cells and osteoclasts, where they play an essential
role in proton transport across the membrane [2]. In mammalian cells,
several subunits of the V1 and V0 domains are expressed as multiple
isoforms. Subunits B, C, E, H, d and e are expressed as two isoforms,
subunit G as three isoforms and subunit a even exists in 4 different
isoforms (Table 1) [7–11]. Expression analysis has revealed that many
isoforms are ubiquitously expressed while other isoforms are limited
to certain cell types [12]. This isoform complexity is thought to be
necessary for tissue- and organel speciﬁc targeting of the V-ATPases
and may also contribute to the control of their activity.
2.1. Structure of the V1 domain and function of the subunits
The subunits of the V1 domain of the ATPase are organized in (i) a
ring shaped hexameric head consisting of three copies of A and B, (ii) a
Fig. 1. Structure and function of the V-ATPase. ATP binds to and is hydrolysed by the A
and B subunits of the hexameric head (light grey). This generates a rotational
movement of the head and the central stalk or rotor, composed of subunits D, F and d
(dark grey), which is transferred to the proteolipid ring (subunits c and c″, white).
Subunit a (black) and the peripheral stalks (subunits C, E, G and H, medium grey) are
static. The conformational changes generated by the rotational movement stimulate the
transfer of a proton along the a-subunit and the proteolipid ring.
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and (iii) peripheral stalks composed of subunits C, E, G and H of V1
and the N-terminal domain of the V0 subunit a. The two types of stalks
connect the V1 domain to the V0 domain (Fig. 1 and Table 1) [13].
2.1.1. Subunits A and B
Three copies of A and three copies of B alternate in the ring-shaped
head of V1. The six ATP binding sites are located at the interfaces
between the A and B subunits, whereas the three catalytic sites are
located solely on the A subunits. Some residues of the B subunit make
contact with these sites, but this is not an essential interaction for
catalysis. In the B subunit, several non-catalytic sites have been
described that are hypothesized to play a role in the regulation of
ATP hydrolysis [14–19]. A unique domain of the A subunit, called the
“non-homologous region” plays an important role in the control of
ATP-hydrolysis, associated with proton translocation, through the
reversible dissociation of the two V-ATPase domains [20]. This non-
homologous region forms a separate domain on the outer surface of
V1 and may contribute to peripheral connection between V1 and V0,
controlling the tightness of coupling of the two domains. Two
isoforms of the B subunit are known in humans: the B1 isoform is
present in kidney but has not been detected in pancreas, muscle, liver,
lung, brain or heart, whereas the B2 isoform is expressed at a basal
level in all tissues analyzed, with a higher level in the human brain and
kidney [7].
2.1.2. Peripheral stalk or stator: subunits a, C, E, G, and H
The peripheral stalk, which spans nearly the entire length of the
outer surface of V1, is composed of subunits C, E, G, H and the N-
terminal region of V0 subunit a [21]. Cross-linking and electron
microscopy studies have provided evidence that there are two
peripheral stalks in the V-ATPase [22–24]. The E and G subunits are
essentially structural elements. Whereas E spans the entire length of
the V1 outer surface, the G subunit is present near the top of the
complex [25,26]. Recent studies by Ohira et al. have shown that the
two peripheral stalks connecting the two V-ATPase domains are both
based on an EG dimer [24]. Venzke et al. suggested that the EGcomplexes could be bound to different sets of other stator subunits
such as C and H, while Fethiere et al. provided evidence for a complex
of E, G and C subunits. Thus, the ﬁrst peripheral stalk contains an EGC
complex and the second one an EGH complex, both interacting with
the N-terminal domain of subunit a [22,23]. The E and G subunits are
expressed as more than one isoform. G1 is ubiquitously expressed,
while G2 is brain speciﬁc and G3 is detected exclusively in kidney
[12,27]. Similarly, E2 is expressed in all tissues, as opposed to E1which
is a testis-speciﬁc isoform [28]. Subunit C, which is located near the
interface of the V1 and V0 domains, is suggested to control the
interaction between the two domains [29]. Whereas the C1 isoform of
this subunit is expressed throughout several different tissues, the C2
isoform is speciﬁcally expressed in placenta and kidney [12]. Subunit
H has also been shown to regulate V-ATPase activity, as it suppresses
the ATP hydrolytic activity of the soluble V1 domain [30]. Based on
cross-linking and electron microscopy studies, subunit H is suggested
to be localised to the peripheral stator near the interface between V1
and V0 [31]. Mutation analysis has demonstrated that subunit H
bridges the peripheral and central stalks and serves as a mechanical
brake to prevent ATP-driven rotation [32]. All subunit isoforms are
encoded by different genes, except the two known H isoforms, which
seem to be splice variants of the same mRNA [33,34].
2.1.3. Central stalk or rotor: subunits d, D, and F
The main function of the central stalk, composed of D and F
subunits of V1 and the d subunit of V0, is coupling of the ATP-
hydrolysis and proton transport. Cross-linking experiments have
proven the strong interaction between these subunits in bovine V-
ATPases [35,36]. In addition, cysteine-mediated cross-linking studies
showed that D interacts with B subunits at sites predicted to be
oriented toward the centre of the A3B3 hexameric head [21,25].
2.2. Structure of the V0 domain and function of the subunits
2.2.1. The proteolipid ring: subunits c and c″
The main component of the V0 domain is a proteolipid ring,
formed by 4 or 5 copies of subunit c (17 kDa) and a single copy of
subunit c″ (23 kDa). These highly hydrophobic proteins contain a
number of transmembrane helices with buried glutamic acids that
are important for proton translocation across the membrane
[13,37–40].
2.2.2. Subunits d and e
Subunit d interacts directly with the D and F subunits of the
central stalk, and is also known to associate with the proteolipid ring
of the V0 domain [9,41]. Its speciﬁc shape provides the contact
surface needed to couple the stalk to the proteolipid ring. Because of
its location, the d subunit is likely to play the connecting role in the
rotary mechanism of the ATPase [9]. In man, two isoforms of subunit
d exist, a d1 isoform that is ubiquitously expressed and a d2 isoform
essentially expressed in kidney and osteoclasts [12]. The membrane-
bound subunit e is known to be essential for V-ATPase function, yet
its exact location and function within the V0 domain are still
unknown [42,43].
2.2.3. Subunit a
The V0 subunit a is a 100 kDa protein that presents a two-domain
structure: an N-terminal, hydrophilic domain extending along V1, and
a hydrophobic C-terminal domain containing multiple transmem-
brane helices [44]. The N-terminal domain is responsible for
intracellular targeting of the V-ATPase towards the appropriate
organel membrane. In addition, experiments have shown that in
yeast, in vivo dissociation of V-ATPase in response to glucose
deprivation is controlled by this N-terminal domain [45]. The last
two transmembrane helices of the C-terminal domain contain critical
arginine residues that are required for proton transport. Through
Table 1
Tissue-speciﬁc localisation and function of human V-ATPase subunits.
Subunit
isoform
Gene
name
Chromosomal
localisation
Swiss-Prot entry
namea
Swiss-Prot acc.
numbera
Tissue Function References
V1 domain
A ATP6V1A1b 3q13.2–q13.31 VATA_HUMAN P38606 Ubiquitous ATP binding and hydrolysis [130]
Control of ATP hydrolysis
B1 ATP6V1B1 2p13.1 VATB1_HUMAN P153131 Kidney, epididymis ATP binding [131]
B2 ATP6V1B2 8p22–p21 VATB2_HUMAN P2128 Ubiquitous Regulation of ATP hydrolysis
C1 ATP6V1C1 8q22.3 VATC1_HUMAN P21283 Ubiquitous Regulation of V1–V0 interaction [132–135]
C2 ATP6V1C2 Chr. 2 VATC2_HUMAN Q8NEY4 Placenta, lung, kidney Element of peripheral stalk/stator
D ATP6V1D 14q23–q24.2 VATD_HUMAN Q9Y5K8 Ubiquitous Element of central stalk/rotor [136,137]
E1 ATP6V1E1 22q11.1 VATE1_HUMAN P36543 Testis Structural element of peripheral stalk/
stator
[28,133,138]
E2 ATP6V1E2 2p21 VATE2_HUMAN Q96A05 Ubiquitous
F ATP6V1F 7q32 VATF_HUMAN Q16864 Ubiquitous Element of central stalk/rotor [139,140]
G1 ATP6V1G1 9q32 VATG1_HUMAN O75348 Ubiquitous Structural element of peripheral stalk/
stator
[140]
G2 ATP6V1G2 6p21.3 VATG2_HUMAN O95670 Brain, neuronal tissue
G3 ATP6V1G3 1q31.3 VATG3_HUMAN Q96LB4 Kidney, epididymis
H1 ATP6V1Hc 8q11.2 VATH_HUMAN Q9UI12 Unknown Regulation of ATP-hydrolysis [31,84]
H2 Element of peripheral stalk/stator
V0 domain
a1 ATP6V0A1 17q21 VPP1_HUMAN Q93050 Neuronal tissue Intracellular targeting of ATPase, [79,141–
146]
a2 ATP6V0A2 12q24.31 VPP2_HUMAN Q9Y487 Ubiquitous Proton pumping across membranes
a3 ATP6V0A3b 11q13.2 VPP3_HUMAN Q13488 Osteoclast Regulation of versicle formation,
(TCIRG1)
a4 ATP6V0A4 7q33–q34 VPP4_HUMAN Q9HBG4 Kidney, inner ear,
epididymis
pH sensor and regulator
c ATP6V0C 16p13.3 VATL_HUMAN P27449 Unknown Proteolipid ring, proton transfer [147–149]
Vesicle budding
c″ ATP6V0B 1p32.3 VATO_HUMAN Q99437 Unknown Proteolipid ring, proton transfer [150,151]
d1 ATP6V0D1 16q22 VA0D1_HUMAN P61421 Ubiquitous Connection of rotor with proteolipid
ring
[133,152–
154]d2 ATP6V0D2 Chr. 8 VA0D2_HUMAN Q8N8Y2 Kidney, epididymis
e1 ATP6V0E1 5q35.2 VA0E1_HUMAN O15342 Unknown Unknown [43,135,155]
e2 ATP6V0E2 7q36.1 VA0E2_HUMAN Q8NHE4
In order to reﬂect our interest in the structure of the V-ATPase, we have chosen to retain the ATP6V⁎ nomenclature.
a Source: www.expasy.org/.
b Smith A.N. et al. [136] deﬁned different ofﬁcial names for these subunits.
c Subunit H has two isoforms, generated by two different splice variants of the same gene.
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residues of the proteolipid ring [44]. The models for the transmem-
brane topology of the a subunit either predict eight or nine
transmembrane helices [46]. However, an uneven number of helices
is suggested by the fact that residues at the C-terminus cannot be
modiﬁed by membrane impermeable agents [47]. Leng et al. have
shown in yeast that mutations of speciﬁc residues in this domain not
only affect the assembly of the V-ATPase, but also result in
mistargeting of the subunit [48].
Four isoforms of subunit a are known, and their role in targeting
the V-ATPase to speciﬁc locations is supported by data from
mammalian cells. Mammalian isoforms share about 50% overall
identity, with higher conservation within the transmembrane regions
[49]. Broad and overlapping mRNA expression patterns were demon-
strated for a1, a2 and a3, but each of the subunits is known to
predominate in special compartments of some cell types [49–51]. In
contrast, the protein distribution is less well characterized and data
are often contradictory due to the different speciﬁcity and sensitivity
of the antibodies used. The a1 isoform has been described to be highly
expressed in brain and to reside in synaptic vesicles, which was
corroborated by mass spectrometric analysis [52]. However, a1 is not
speciﬁc for this compartment as indicated by the fact that it was
detected in the Golgi proteome, together with a2 [53]. Fractions
enriched for kidney brush border contain subunits a1, a2 and a4 [51].
In kidney-derived MDCK cells, a2 does not reside in the Golgi, but
rather in early endosomes [50]. The a3 isoform is mostly expressed in
late endosomes and lysosomes and in the osteoclast rufﬂed
membrane that is derived from these vesicles [54]. Other data suggest
a localisation of a3 in secretory granules in pancreatic beta cells [55].
In contrast to the other a-subunits, expression of a4 is highly restrictedto the kidney and the inner ear. An apical localisation of the a4 isoform
in α-intercalated cells is known [56,57]. Interestingly, the a4 and B1
distribution are highly similar [57].
3. Localisation, function and regulation of V-ATPases
3.1. Cellular and subcellular localisation of V-ATPases
V-ATPases are present in various subcellular compartments in all
mammalian cells. As described in the previous section, different
isoforms of numerous subunits are known. The composition of these
isoforms within the V-ATPase complex and the expression levels are
varying in a cell type- and subcellular compartment-speciﬁc manner
[58,59]. Thus, there are different levels of regulation to ensure the
optimal ﬁne tuning of the V-ATPase activity according to the needs of
each subcellular compartment.
High V-ATPase expression levels are found in some specialized cell
types. The osteoclast is a prominent example, but also renal
intercalated cells, macrophages, neutrophils and epididymal cells
show strong V-ATPase expression. In osteoclasts, the vacuolar H+-
ATPase is essential for bone resorption. The ATPase complex is
recruited to the plasma membrane by fusion of late endosomes which
leads to the formation of the rufﬂed border membrane (Fig. 2) [54,60].
Renal intercalated cells strongly express V-ATPase to control acid-base
balance by secretion of acid via the plasma membrane (Fig. 2) [59]. In
rat epididymis and vas deference the V-ATPase complex is found on
the apical membrane of epididymal clear cells. In neutrophils V-
ATPases are localised in intracellular vesicles and at the plasma
membrane. Further cell types that express V-ATPases on their plasma
membrane are the insect midgut cells and some invasive tumour cells
Fig. 2.Multiple roles of V-ATPase in pH regulation and vesicle function. Themain function of V-ATPases is the regulation of the luminal pH of different intracellular compartments, the
extracellular space and the cytoplasm. (a) In osteoclasts, V-ATPase is recruited from late endosomes/lysosomes to the cell surface membranewhere it acidiﬁes the resorption lacuna,
also called an “extracellular lysosome”. (b) V-ATPase controls the acid-base balance by pumping protons via the plasma membrane of alpha-intercalated cells into the renal tubule.
(c) Receptor-mediated endocytosis: V-ATPase provides the acidic pH in endosomes necessary for the release of internalized ligands from their receptors and the recycling of the
unoccupied receptors back to the cell surface. The sorting and trafﬁcking of different kinds of endocytosed physiologically (e.g. growth factors) and pathologically (e.g. toxins)
relevant cargo is also inﬂuenced by V-ATPases. (d) The V0 domain is suggested to play a role in different exocytic events: (d1) V-ATPase with a1-subunit has special importance for
neurotransmitter release in neuronal cells. (d2) The a3 subunit has been shown to be involved in insulin secretion. (d3) Possible role of the a2 subunit for the secretion of extracellular
matrix components as indicated by defective elastic ﬁbres in patients with autosomal recessive cutis laxa type 2.
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most cases those that show a plasma membrane localisation of the V-
ATPase complex.
This plasma membrane localisation, however, is a more recent
evolutionary invention since the vacuolar-type ATPases got their
name because they were identiﬁed in the yeast vacuole. In contrast,
the proton pumps localised at the yeast plasma membrane belong to
the P-ATPase family. In mammalian cells, the V-ATPase was found in
many intracellular compartments. Localisation in vesicles of the
endocytic pathway like early, late and sorting endosomes as well as
lysosomes is long known [61]. Many groups have shown that the V-
ATPase is also localised in secretory and synaptic vesicles and in the
Golgi compartment [50,53,55,62,63]. In all these intracellular com-
partments, V-ATPase is involved in regulation of pH-homeostasis,
membrane trafﬁcking and vesicle fusion.
3.2. Regulation of V-ATPases
Several mechanisms are described for V-ATPase regulation,
including V1/V0 domain dissociation, change of their cellular
localisation and the efﬁciency of proton transport and ATP hydrolysis.
Reversible dissociation of the V1 and V0 domains takes place in
response to different stimuli such as glucose depletion and
activation of antigen processing [64]. It is suggested that dissocia-
tion and assembly are two independently controlled processes. Adisruption of the microtubular network inhibits glucose-dependent
dissociation of V-ATPase without affecting reassembly [65]. In
contrast, reassembly requires a novel protein complex called RAVE
(regulator of the ATPase of vacuolar and endosomal membranes)
[66]. RAVE interacts with dissociated V1 sectors via the subunits
E and/or G [67].
Aldolase is also proposed to regulate the V1–V0 complex
assembly in a glucose-dependent fashion [68]. This function depends
on the interaction of aldolase with the B subunit, but does not
require enzymatic activity [69]. An interaction of the a-subunit of the
V0 domain (possibly the N-terminal cytoplasmic domain) and the A
subunit of the V1 domain has also been implicated in glucose
sensing [70].
The density of proton pumps at the surface of several cell types is
controlled by reversible exo- and endocytosis. In epididymal clear
cells, recycling of V-ATPases between intracellular compartments and
the apical membrane is regulated by adenylyl cyclase (sAC) [71]. The
presence of a sAC in numerous secretory epithelia, including renal
intercalated cells, suggests that this might represent a common
mechanism for V-ATPase regulation. The actin cytoskeleton also
appears to have an important role in the regulation of V-ATPase
localisation. Modulation of the actin cytoskeleton via gelsolin is
proposed to regulate V-ATPase recycling [72]. Alterations of the
coupling efﬁciency between proton transport and ATP hydrolysis have
been proposed to modulate acidiﬁcation [61]. Although there is
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responsible in vivo remain to be further investigated.
3.3. Physiological functions of V-ATPases
V-ATPases serve a number of functions in normal physiology
mainly by regulating the pH of different intracellular compartments,
the extracellular space and the cytoplasm.
3.3.1. Functions of intracellular V-ATPases
The acidic pH that V-ATPases produce in endosomes generated
by receptor-mediated endocytosis induces the release of inter-
nalized ligands from their receptors [61]. This facilitates the
recycling of the unoccupied receptors back to the cell surface and
the targeting of the released ligands to the lysosome for
degradation [3]. Typical examples for this type of transport are,
among others, the cholesterol carrier low density lipoprotein (LDL),
asialoglycoproteins, peptide hormones (e.g. insulin) and growth
factors (e.g. EGF) (Fig. 2) [5]. The lysosomal enzymes synthesized
in the Golgi compartment are transported to the lysosome partially
by a similar mechanism by binding to the mannose-6-phosphate
receptor [3,73].
V-ATPases also appear to play a role in the formation of endosomal
carrier vesicles from sorting endosomes that transport the uncoupled
ligands to later endosomal compartments. Budding of these vesicles
requires the binding of beta-COP coat proteins to the early endosomal
membrane, and is dependent upon the acidic lumenal pH generated
by the V-ATPase [3].
Hurtado-Lorenzo et al. suggested that the V-ATPase also operates
as a scaffold protein to recruit factors involved in trafﬁcking [50].
It was shown that ARNO (ARF nucleotide-binding site opener)
binds to the N-terminus of subunit a2 of the V-ATPase, which
localises to early endosomes and the Golgi compartment [53].
ARNO is the guanine exchange factor (GEF) for Arf6 (ADP-
ribosylation factor 6) which in the same study was shown to
bind to the subunit c of the V0 domain in a pH-dependent manner.
This interaction between V-ATPase, Arf6 and ARNO implicates a
direct, pH-dependent inﬂuence of the V-ATPase on membrane
budding for which Arf6-recruitment is a crucial step. After budding
and uncoating, the vesicles are tethered to the acceptor compart-
ment via tethering factors and v- and t-SNARE proteins [74]. After
the vesicle membrane has been brought in close contact with the
target membrane both membranes must fuse to form a pore. The
V0 domain of V-ATPases has been implicated in this fusion process
according to studies about fusion between vacuoles in yeast [75]. It
is suggested that the V0 domains of opposing membranes form
pairs with each other, which leads to the assembly of fusion pores
[76]. Furthermore, V-ATPases have been shown to play a role in
exocytic processes like synaptic vesicle release in Drosophila [77],
exosome release of Hedgehog-related proteins in Caenorhabditis
elegans [78] and secretion of insulin by pancreatic islet cells [55]. In
some of these studies, it was demonstrated that the effect of the
loss of the a-subunit in the mutants was different from the effect of
the V-ATPase inhibitor baﬁlomycin. This indicates that the V0
domain might be able to directly mediate vesicle fusion by
catalyzing the mixing of the two lipid bilayers due to its highly
hydrophobic subunit composition.
Lumenal pH regulation is also crucial for posttranslational
modiﬁcation in the Golgi compartment. While the pH of the cis
cisterna is close to neutral, the trans cisterna has a pH around 6. Like
all enzymes, glycosyltransferases have a pH optimum for function and
therefore disturbance of pH regulation in the Golgi could lead to
glycosylation defects. The pH gradient formed by V-ATPases is also
used for different types of secondary active transport. Several
neurotransmitter-proton antiporters are essential for the transport
of neurotransmitters into synaptic vesicles [79].3.3.2. Functions of plasma membrane V-ATPases
In a variety of cell types, particularly cells of epithelial origin, V-
ATPases are present in the plasma membrane where their major
function is acid secretion. In the kidney, this applies to proximal
tubular cells, as well as both alpha- and beta-intercalated cells of the
distal tubule and the collecting duct [3]. Proximal tubule cells reabsorb
bicarbonate, by ﬁrst converting it into CO2 that can cross the apical
membrane. This conversion takes place when acid is secreted into the
lumen by the proximal tubular cells. The secretion of acid is carried
out by plasma membrane V-ATPases and apical membrane Na+/H+
exchangers. In the distal tubule and the collecting duct, the V-ATPases
are involved in secretion of acid or base equivalents into the urine.
Alpha-intercalated cells contain V-ATPases at the apical membrane
and Cl−/HCO3− exchangers at the basolateral membrane. V-ATPases
are responsible for proton secretion from the cytoplasm into the
lumen, whereas the Cl−/HCO3− exchanger releases HCO3− across the
basolateral membrane and prevents alkalinisation of the cytoplasm
[60]. To the contrary, intercalated cells which express the V-ATPase
basolaterally serve to reabsorb acid equivalents.
In osteoclasts, V-ATPase complexes are found at the cell surface
and have a crucial role in bone resorption [60]. Osteoclasts attach to
the bone surface and seal off a portion of the extracellular space. Acid
and digestive enzymes that dissolve the bone matrix are secreted into
this space that thereby becomes a resorption lacuna. V-ATPases in this
domain of the osteoclast cell surface, called the rufﬂed border, are
responsible for acid secretion [80]. The a3 subunit of the Vo domain is
prerequisite to direct the V-ATPase complexes to the rufﬂed border
[54]. Furthermore, V-ATPases present at the apical plasma membrane
of clear cells in the vas deferens and epididymus play the main role in
maintenance of luminal pH at a relatively low value. This low pH is
important for sperm maturation [71]. In macrophages and neutro-
phils, V-ATPases provide proton efﬂux from the cell. This is necessary
because these types of cells are often found in highly acidic
environments such as infected regions or tumours. Thus, they demand
great acid secretion capacity in order tomaintain their neutral pH [13].
V-ATPases also seem to participate in angiogenesis for which invasion
and migration of microvascular endothelial cells is essential. In these
cells, plasmamembrane V-ATPases have been identiﬁed at the leading
edge, where they appear to play a role in both processes [81].
3.3.3. Pathophysiological aspects
Envelope viruses and bacterial toxins, such as inﬂuenza virus,
Semliki forest virus, vesicular stomatitus virus (VSV), diphtheria toxin
and anthrax toxin, enter cells via acidic endosomal compartments
(Fig. 2). In these compartments low pH induces the formation of a
membrane pore through which the viral mRNA or cytotoxic portions
of the toxin molecules can be translocated into the cytoplasm [82]. For
example, the binding of inﬂuenza virus to a cell surface receptor is
followed by internalization via clathrin-coated vesicles. Reaching early
endosomes, the acidic environment produced by the V-ATPase
triggers the fusion of the viral and endosomal membranes, which
creates a fusion pore and results in release of the viral RNA into the
cytoplasm of the host cell [61]. In the case of toxins, entry occurs either
directly from sorting endosomes, or ﬁrst into the vesicles contained in
multivesicular bodies followed by release into the cytoplasm from late
endosomes [83]. Furthermore, V-ATPases have been implicated in
infection of cells by HIV. Subunit H of the V-ATPase appears to play a
role in the internalization of the HIV receptor CD4 [84]. In addition to
this role in entry of viruses and toxins, it has been shown that the E5
oncoprotein of bovine papilloma virus causes an inhibition of
endosomal and Golgi acidiﬁcation through binding to the c subunit
of the V-ATPase [36]. Mutations in E5 that disrupt interactionwith the
c subunit both prevent inhibition of acidiﬁcation and block the ability
of E5 to transform cells [85]. Martinez-Zaguilan et al. found that highly
invasive MB231 breast-tumour cells exhibited signiﬁcant plasma
membrane V-ATPase activity in comparison to the poorly metastatic
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could be enhanced by a low extracellular pH created by V-ATPases
[61,87]. In these cells V-ATPases may play an additional role by
improving drug resistance. It has been shown that drug-resistant
tumour cell lines show increased expression of V-ATPase subunits
[87]. Thus, V-ATPases could be a potential drug target to increase the
drug sensitivity of tumours.
3.4. Phenotypes elicited by V-ATPase mutations not found in humans
Two isoforms of the d subunit, d1 and d2, exist in human and mice
which exhibit high similarity [10]. The d2 isoform is expressed mainly
in the kidney and at lower levels in heart, spleen, skeletal muscle, and
testis, whereas d1 was detected in various tissues [88].
It was shown that the inactivation of Atp6v0d2 in mice results in
normal growth and development [89]. Despite the high expression of
d2 in the kidney urine pH was normal. However, Atp6v0d2−/−
animals showed a strikingly increased bone mass reminiscent of
osteopetrosis. Increased cartilage remnants and reduced serum type 1
collagen cross-linked C-terminal telopeptide indicated a decreased
bone resorption activity. Although d2 was not detectable in
osteoblasts, osteoblast number and bone formation rate were
signiﬁcantly increased. In vitro investigations revealed that
Atp6v0d2−/− osteoclasts were much smaller due to impaired
progenitor cell fusion. When the in vitro resorption activity of mutant
osteoclasts was normalized by the number of multinucleated
osteoclasts it was undistinguishable from wildtype. Therefore, the
d2 subunit, in contrast to the a3 subunit (see above), does not play a
role in acid secretion via the rufﬂed border, but by a yet unknown
mechanism regulates fusion of osteoclast progenitors.
Peri and Nuesslein-Volhard demonstrated that knock down of the
V-ATPase a1 subunit in zebra ﬁsh leads to defects in brain
development due to the reduced phagocytotic removal of apoptotic
neurons by microglial cells [63]. Normally, the phagolysosomes
required for this process are formed by fusion of many acidic vesicles.
The defective generation of phagolysosomes after knock down of the
a1 subunit shows that the a1 subunit mediates fusion between
phagosomes and lysosomes duringmicroglial phagocytosis, a function
that is independent of its proton pump activity.
In Drosophila mutations in the vha-100 gene encoding the a1
subunit lead to impaired photoreceptor function due to a defect
in synaptic transmission [77]. Subsequent analysis demonstrated
that lack of a1 unexpectedly did not impair loading of synaptic
vesicles with neurotransmitters, but their fusion with the
presynaptic membrane.
4. Human phenotypes arising from mutations in
V-ATPase subunits
Genetic defects in V-ATPase genes have been associated with
hereditary human diseases. Mutations in four known genes encoding
speciﬁc subunits of V-ATPases have been identiﬁed so far.
4.1. Infantile malignant autosomal recessive osteopetrosis (ARO)
Infantile malignant osteopetrosis (MIM: 259700) is a rare auto-
somal recessive disease with an average incidence of 1:200,000 to
1:300,000 [90]. It is characterized by high bone density due to a failure
of osteoclasts to resorb bone. The clinical features comprise abnormal
bone remodelling, deﬁcient haematopoiesis, and neurologic impair-
ment owing to narrowing of the foramina [90]. Bony encroachment
can cause facial nerve entrapment resulting in facial palsy, visual
impairment and optic atrophy, hearing loss, and difﬁculties with
swallowing and feeding [90,91]. The disease is most commonly
diagnosed soon after birth or within the ﬁrst years of life with
symptoms of variable severity such as anaemia caused by bonemarrow failure, nystagmus, hepatosplenomegaly, hypertelorism,
psychomotor retardation, and nasal congestion [92]. Seventy-ﬁve
percent of patients, when untreated, die by the age of 4 years as a
consequence of recurrent infections such as osteomyelitis and
pancytopenia [93]. The diagnosis can be made on the basis of
characteristic radiologic changes [94] and should be conﬁrmed by
molecular genetic analysis. Diffuse sclerosis of the spine and long
bones [95] and modelling defects at the metaphyseal ends of long
bones, resulting in typically widened and blunted diaphyses and
metaphyses (‘Erlenmeyer ﬂask’ deformity) are the most typical
radiographic features [94]. ‘Bone-in-bone’ appearance can be present
in the vertebrae, phalanges, long bones, and pelvic bones. Mutations
in the a3 subunit (ATP6V0A3, TCIRG1, MIM: 604592) of the V-ATPase
have been found to be causative for ARO [54,91]. Most mutations
entail a loss of function of the encoded protein. Since early bone
marrow transplantation provides the only curative treatment for
malignant forms of osteopetrosis an early clinical, radiologic and
genetic diagnosis is crucial for the prognosis [96].
4.2. Autosomal recessive renal tubular acidosis with and without
sensorineural deafness
Distal renal tubular acidosis (dRTA) is a rare genetic disease in
which the intercalated cells in the collecting duct fail to secrete the
protons required for urinary acid excretion. The dRTA is classiﬁed into
four different types according to the mode of inheritance and the
presence of hearing impairment. Different forms have been described:
a) a dominant type of dRTA, b) a recessive type without hearing loss,
c) a recessive type with early onset of sensorineural deafness (MIM:
267300) and d) a recessive type with later onset of sensorineural
deafness (MIM: 602722) [97]. The clinical severity is very variable,
ranging from compensated mild acidosis, absence of symptoms, and
the incidental ﬁnding of kidney stones and/or renal tract calciﬁcation
to major effects in infancy with severe acidosis, impaired growth, and
early nephrocalcinosis causing eventual renal insufﬁciency in combi-
nation with progressive and irreversible bilateral sensorineural
hearing loss [98]. If untreated, this acidosis may result in dissolution
of bone, leading to osteomalacia and rickets. In 1999, Karet et al. ﬁrst
associated mutations in the AT6B1 gene to dRTA with sensorineural
deafness [99]. ATP6V1B1 encodes the V-ATPase B1 subunit. Northern
Blot analysis revealed high expression of ATP6V1B1 in human kidney
and cochlea. By immunohistochemistry the protein was detected in
the apical membrane of the renal α-intercalated cells of the distal
tubule [99]. Mutations introduce premature termination codons,
frameshift mutations, splice-site mutations and non-conservative
missense substitutions. Subsequently, mutations in another V-ATPase
gene, ATP6V0A4, were identiﬁed in kindreds with recessive renal
tubular acidosis [57]. The gene encodes subunit a4 of the vacuolar H+-
ATPase, which was found to be exclusively expressed in foetal and
adult kidney. While ATP6V1B1 mutations are associated with early
sensorineural hearing loss (SNHL), ATP6V0A4mutations are classically
associated with either late-onset SNHL or normal hearing. Vargas-
Poussou R. et al. assessed the phenotype and genotype of 39 families
with recessive dRTA [100]. Unexpectedly, 7 out of the 21 probands
with mutations in ATP6V0A4 developed severe hearing loss at young
age. This study demonstrates that mutations in either of these genes
may cause early deafness.
5. Cutis laxa
Recently, defects in the V-ATPase a2 subunit due to mutations in
the ATP6V0A2 gene have been shown to cause an autosomal recessive
form of cutis laxa in combination with glycosylation defects [1,101].
Cutis laxa is a rare inherited disorder of the connective tissue
characterized by excessive sagging of skin folds and decreased
elasticity of the skin. Patients suffering from cutis laxa present with
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associated with variable organ involvement and severity. One of the
major diagnostic criteria is the detection of decreased amounts of
structurally abnormal elastin ﬁbres in the skin biopsy, which can,
however be missing in some clinically similar, mostly autosomal
recessively inherited cases. In most patients diagnosed with cutis laxa
syndrome the underlying genetic cause is not known. Due to overlap
in the phenotypes and signiﬁcant clinical variability the exact clinical
diagnosis remains challenging [102]. Dominant, recessive and x-
chromosomal modes of inheritance have been described.
The autosomal dominant form of cutis laxa syndrome (ADCL;MIM:
123700) is relatively mild, compared to the recessive neonatal form
[103]. Systemic involvement seldom occurs except for cardiac
symptoms [104]. Some patients with autosomal dominant inheritance
carryﬁbulin-5 (FBLN5) genemutations, or deletions in the elastin gene
(ELN) [104,105]. The X-linked variant (XLCL; MIM: 304150) is due to a
defect of the cellular copper transport and has a wide phenotypic
spectrum, and a combination of skeletal and internal organ involve-
ment [106]. This disorder is allelic to Menkes disease, and is caused by
mutations in the copper transporter gene ATP7A [107].
5.1. Autosomal recessive cutis laxa
The most severe forms of cutis laxa are inherited in an autosomal
recessive fashion and are frequently lethal in the neonatal period
(ARCL I; MIM: 219199). Besides cutis laxa, patients show arterial
tortuosity, emphysema, diverticulae of urinary and gastrointestinal
tract. Mutations in the ﬁbulin-4 (FBLN4, EFEMP2) gene [108] or the
ﬁbulin-5 (FBLN5) gene [109,110] have been detected in children with
ARCL I.
Patients classiﬁed as autosomal recessive cutis laxa type II (ARCL II,
ARCL Debré type; MIM: 219200) [111,112] have a much better clinical
outcome than those with a severe, multisystemic form (ARCL I; MIM:
219199). In ARCL II children, cutis laxa is associated with prenatal and
postnatal growth retardation, delayed closure of large fontanels,
congenital hip dislocation, osteoporosis, dental caries and a char-
acteristic facial appearance (down-slanting palpebral ﬁssures, broad
ﬂat nasal bridge, anteverted nostrils, large ears). There is a develop-
mental delay in some of the cases. Osteoporosis and decreased bone
density have been reported in many patients. Within the same clinical
group there is biochemical heterogeneity: a congenital combined N-
and O-linked disorder of glycosylation can be detected in some of the
patients (see below) [1,101,112].
Patients with De Barsy syndrome, included in ARCL III (MIM:
219150), show signiﬁcant phenotype overlap with ARCL II, but no
patient has been reported so far with combined glycosylation
anomalies. The underlying genetic aetiology of this unique, progres-
sive disorder is still unknown [113]. One should mention two
additional clinical syndromes in the clinical spectrum of ARCL
syndromes. Gerodermia osteodysplastica (GO; MIM: 231070) [114],
presents with several features similar to ARCL II, including congenital
cutis laxa and skeletal ﬁndings, including generalized osteoporosis
and increased fracture rate. GO is caused by mutations in the gene
SCYL1BP1 encoding a novel Golgi protein [115]. Another similar entity
is wrinkly skin syndrome (WSS; MIM: 278250) [114], a mild variant of
ARCL II, without signiﬁcant histological abnormalities, and a
biochemical and genetic heterogeneity.
5.2. Clinical features in ARCL II
Recently, missense and nonsensemutationswere discovered in the
ATP6V0A2 gene in several families diagnosedwith autosomal recessive
cutis laxa type II and wrinkly skin syndrome, suggesting that both are
phenotypic variants of the same disorder [1,101,112]. ARCL II and WSS
patients with a ATP6V0A2 mutation have generalized skin abnormal-
ities, skeletal, neuromuscular and central nervous system involvementin variable degree with or without mental retardation. Their perinatal
history is mostly normal, and generalized cutis laxa is present already
at birth. Skin biopsy in the most severe cases demonstrates an
abnormal, broken, shortened and fuzzy elastic ﬁbre structure with a
signiﬁcantly decreased amount of elastin. The skin anomalies became
less obvious, and sometimes disappearwith age. Cardiac anomalies are
rare. Many of the patients have congenital hip dislocations and
increased joint laxity. The systemic involvement is verymild, including
elevated liver enzyme activities and slightly abnormal coagulation in a
very few patients. Common ophthalmologic abnormalities are stra-
bismus, myopia or amblyopia. Congenital or progressive microcephaly
is the most common associated feature in patients. Congenital brain
malformations are extremely rare. Although developmental delay can
be observed in the majority of the children the motor development
improves in most cases with age. One might suspect that the motor
delaywas partially due tomuscle hypotonia, and in some degree to the
hyperelastic joints. Most of the children demonstrate a normal mental
development and only a minority shows intellectual disability [1,101].
So far, all patients with ATP6V0A2 mutations show a combined defect
in the biosynthesis ofN- andO-linked glycans. This can easily be picked
up with the technique of plasma transferrin isofocusing (see below in
“Defects in the ATP6V0A2 gene lead to a combined defect in N- and O-
glycosylation”). No speciﬁc clinical features have been found distin-
guishing the group of patients having the glycosylation abnormalities,
and remaining patients within the diagnostic group of ARCL II.
Apparently, the frequency of central nervous system malformations
is somewhat higher in the group with CDG, but congenital brain
malformations have been described in the groupwithout glycosylation
defect as well [101].
5.3. CNS abnormalities in ARCL II
Congenital brain anomalies seldom occur in ARCL II. Motor
developmental delay is common but low normal in most cases. A
unique ﬁnding is the presence of developmental brain abnormalities
such as migration defects (cobble-stone like brain dysgenesis) in a
couple of cases [1]. These are comparable to the brain anomalies found
in congenital O-mannosylation defects (Walker–Warburg syndrome,
Muscle–Eye–Brain disease) [116]. In general, CNS symptoms are less
frequent in ARCL II (including ATP6V0A2 defects) than in patients
with O-mannosylation defects or in patients with classic disorders of
N-glycosylation. In the latter patient group cerebellar hypoplasia,
spasticity, epilepsy, hearing- and visual loss occur relatively frequent.
Neuronal migration is a complex developmental process. Several
disorders of neuronal migration are known, including a group of
disorders caused by defective O-mannosyl glycan synthesis. The most
severe form, Walker–Warburg syndrome (WWS; MIM: 236670) is a
recessive disorder characterized by severe brain malformations,
muscular dystrophy, and congenital eye abnormalities. Another two
similar, but less fatal, diseases are the so called muscle eye brain
disease, (MEB; MIM: 253280) and Fukuyama congenital muscular
dystrophy (FCMD; MIM: 253800).
In brain, several different proteins and glycosylatedmolecules have
been hypothesized to be responsible for the occurrence of develop-
mental defects. Failed interactions with extracellular matrix compo-
nents may underlie the severe neuronal migration that causes the
congenital anomalies in the MEB disease spectrum, such as in the
currently described novel glycosylation defect.
6. Glycosylation defects
Glycosylation is one of the most variable post-translational
modiﬁcations of proteins. It plays an important role in cell migration,
pathway ﬁnding and cellular connectivity, as well as localisation,
interaction and function of glycoproteins. Since 50% of the proteome
consists of glycoproteins that play many different roles in the
Fig. 3. N-glycosylation of transferrin (Tf). Left: N-glycans present on tetrasialotransferrin (▪= GlcNAc, = Man, ○= Gal, = sialic acid); right: iso-electric focusing of human
plasma transferrin. Lane 1: normal IEF proﬁle, lane 2: type I IEF proﬁle, characteristic for N-glycan biosynthesis defects localised in the cytoplasm or the ER (decreased tetrasialo-Tf,
increased disialo- and monosialo-Tf), lane 3: asialo type II IEF proﬁle, characteristic for Golgi based glycosylation defects (decreased tetrasialo-Tf, increase of all hypoglycosylated
forms), lane 4: disialo type II IEF proﬁle, characteristic for patients with cutis laxa due to ATP6V0A2 defect (decreased tetrasialo-Tf, increased trisialo- and disialo-Tf). The double
banding pattern observed in the IEF proﬁles of lane 3 and 4 is due to a polymorphism of transferrin [adapted from 122].
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in a wide variety of congenital malformation syndromes, collectively
called congenital disorders of glycosylation (CDG) [102]. Two types of
glycosylation are known, based on the attachment site of the glycan
on the protein: N- and O-glycosylation.
6.1. N-glycosylation defects
The biosynthesis of N-glycans is a multistep process taking place
in different cellular compartments. It starts in the cytosol, where
nucleotide sugars are synthesized from monosaccharides derived
from dietary sources and recycling processes. Next, in the endoplas-
matic reticulum, a lipid-linked oligosaccharide (LLO), consisting of
dolichol-PP-GlcNAc3-Man9-Glc3, is constructed and transferred to an
asparagine of a nascent protein. Defects in the assembly and transfer
of the LLO result in a congenital disorders of glycosylation type I
(CDG-I) [117]. Finally, the glycoprotein leaves the ER and enters the
Golgi, where N-glycans are processed through the sequential action of
a number of speciﬁc glycosyltransferases and glycosidases in a highly
controlled way. Defects in the processing of N-glycans result in CDG
type II (CDG-II). Fully processed N-glycans present two, three or four
antennae terminated by a negatively charged sialic acid (Fig. 3) [117].
Iso-electric focusing (IEF) of plasma transferrin is an important
tool in diagnosing patients with congenital disorders of glycosylation.
Human plasma transferrin contains two N-glycans, each with 2 or 3
antennae, usually with a negatively charged terminal sialic acid
(Fig. 3). In human plasma of healthy individuals, the tetrasialotrans-
ferrin fraction is themost abundant form, containing two biantennary,
fully sialylated N-glycans. When a genetic defect is present in the early
steps of N-glycan biosynthesis, in the cytoplasm or endoplasmic
reticulum, the ﬂux through the biosynthetic pathway of the LLO will
be overall insufﬁcient. The newly built glycoproteins therefore cannot
be adequately N-glycosylated. The transferrin molecule, normally
acquiring two N-glycans, will then obtain a single or no N-glycan.
Thus, in patients with CDG-I, the percentages of asialotransferrin (no
N-glycan) and disialotransferrin (only one fully built biantennary N-glycan) are increased (Fig. 3). If the defect occurs after transfer of the
oligosaccharide to the protein, the result is a deﬁcient processing of
the glycan antennae and undersialylation thereof. The defect can
inﬂuence biosynthesis and transport of nucleotide sugars or the
activity and localisation of glycosidases and glycosyltransferases. In
addition, proper transport of the glycoprotein from ER to cis-, median
and trans-Golgi cisternae is important for the correct sequential
removal of terminal glucoses and mannoses and the addition of new
monosaccharides to the glycan. Ultimately, complex N-glycans, such
as those present on human transferrin, may present truncated
antennae, thus lacking one or two sialic acids. This leads to a typical
type II transferrin iso-electric focusing pattern, as seen in Fig. 3.
Further biochemical analysis to ﬁnd the exact diagnosis of the CDG
subtype include enzyme measurements, analysis of lipid linked
oligosaccharides and mutation analysis [118].
6.2. O-glycosylation defects
The onset of O-glycosylation takes place in the ER or in the Golgi
apparatus, after folding and oligomerisation of proteins. O-glycans are
attached to the hydroxyl group of serine or threonine, and
occasionally to hydroxylysine. In humans, mucin-type glycans are
the most common form. They are attached to the protein via a GalNAc
and are usually limited in size (1 to 10 residues). Within the mucin-
type O-glycans, 8 core structures can be distinguished, depending on
the second sugar and its glycosidic linkage [119]. Like N-glycosylation,
O-glycosylation starts with the biosynthesis of activated nucleotide
sugars in the cytosol. In the ER and Golgi, O-glycans are assembled in
a highly controlled way by the sequential action of speciﬁc,
membrane-bound transferases, whose localisation is very important.
Complex processes are involved in vesicular transfer between
different cisternae of the Golgi and thus the localisation of the
transferases. Defects in trafﬁcking within the Golgi can affect
structure and function of the whole apparatus, leading to impaired
biosynthesis of glycoconjugates, intracellular protein sorting, and
protein secretion [119].
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strate defects in the biosynthesis of core 1 mucin-type O-glycans,
based on the iso-electric focusing of serum apolipoprotein C-III (apoC-
III). ApoC-III carries one glycan: a core 1 mucin-type O-glycan. As
shown in Fig. 4, this glycan presents with two sialic acids in its fully
synthesized form. The corresponding apoC-III isoform is called apoC-
III2. Two other isoforms exist, based on the number of sialic acids:
apoC-III0 (nonsialylated form) and apoC-III1 (monosialylated form)
[120]. Compared to the isofocusing proﬁle of apoC-III of healthy
individuals, the apoC-III proﬁle of patients with disturbed core 1
mucin-type O-glycan biosynthesis shows increased amounts of apoC-
III0 and/or apoC-III1.
6.3. Defects in the ATP6V0A2 gene lead to a combined defect of
N- and O-glycosylation
As described above, processing of N-glycans and mucin O-
glycosylation both occur in the Golgi apparatus and defects in this
part of the biosynthetic route are characterized by a type II transferrin
isofocusing pattern. Some CDG-II patients also have an abnormal
apoC-III isofocusing proﬁle. A number of factors involved in glycan
biosynthesis are common to the N and O-glycosylation process, such
as nucleotide sugars and their transporters. Also, Golgi trafﬁcking and
structural integrity are crucial for both types of glycosylation.
Combined glycosylation defects have been observed in several
patients, including a group with mutations in one of the subunits of
the Conserved Oligomeric Golgi (COG) complex. This octameric
complex is essential for the structure of the Golgi complex and is
thought to have a role in trafﬁcking between ER and Golgi and
amongst Golgi cisternae [121,122]. Based on transferrin iso-electric
focusing patterns as well as apoC-III iso-electric focusing and SDS-
PAGE proﬁles of serum from CDG-II patients, Wopereis et al. [123]
deﬁned 6 biochemical subgroups among these patients. Surprisingly,
3 out of 4 patients of the subgroup showing disialotransferrin IEF and
apoC-III1 proﬁles, displayed an ARCL II phenotype. These patients
turned out to have a defect in the a2 subunit of the V-ATPase [1].
Subsequently, all patients with cutis laxa due to ATP6V0A2
mutations known to date have been shown to have an abnormal
transferrin isofocusing proﬁle [1,101,120]. The typical so-called disialo-
type II transferrin isoform proﬁle seen in these patients is shown inFig. 4. O-glycosylation of apolipoprotein C-III. Lane 1: iso-electric focusing pattern of a
control; lane 2: apoC-III0 proﬁle of CDG-II patient (decreased apoC-III2, increased apoC-
III0 and apoC-III1); lane 3: apoC-III1 proﬁle characteristic for cutis laxa patients with an
ATP6V0A2 defect (decreased apoC-III2, increased apoC-III1). The picture also shows the
probable O-glycan structure present on the apoC-III isoforms. The nomenclature of the
two apoC-III IEFproﬁles is derived fromWopereis et al. [123]. (□=GalNAc,○=Gal, =
sialic acid) [adapted from 123].Fig. 3, lane 4 [116]. Alongside the N-glycan biosynthesis defect,
patients also have a core 1 mucin-type O-glycan biosynthesis defect.
This is shown by the typical apoC-III1 proﬁle (Fig. 4, lane 3),
characterized by decreased apoC-III2 and increased apoC-III1. It has
been observed that patientsmay have a normal transferrin isofocusing
proﬁle in the ﬁrst months of life, but develop the typical transferrin
abnormality later on. In these patients, the apoC-III isofocusing was
already abnormal in the ﬁrst months of life [124].
7. ATP6V0A2 mutations and their inﬂuence on glycosylation and
elastic ﬁbre formation
While it might be that O-glycosylation defects are responsible for
the brain abnormalities found in ARCL II in analogy to known
disorders of O-glycosylation, the connection between loss of the a2
subunit, Golgi dysfunction and the elastic ﬁbre defect remains elusive.
Also, the exact mechanism by which mutations in the V-ATPase
a2 subunit affect glycosylation remains to be elucidated. Two major
functions of the V-ATPase V0 domain are (i) maintenance of the pH
gradient along the secretory pathway by proton transport and (ii) the
regulation of protein transport through the facilitation of vesicle
fusion [75]. Both processes are closely related, as vesicle acidiﬁcation
can regulate the recruitment of factors involved in vesicle budding
and fusion.
Axelsson et al. [125] have proven that neutralization of the pH
gradient of the secretory pathway results in the relocalisation of
glycosyltransferases such as N-acetylgalactosaminyltransferase 2, β1,2
N-acetylglucosaminyltransferase I and β1,4 galactosyltransferase 1.
They are normally localised in the medial/trans-Golgi and the trans-
Golgi/TGN, respectively. Baﬁlomycin A1, a speciﬁc V-ATPase inhibitor,
causes a relocalisation of these enzymes to the cell surface, while the
general morphology of the ER and Golgi apparatus is retained. In
colorectal carcinoma cells, in vitro neutralization of the pH of whole
cells with NH4Cl leads to a relocalisation of the enzymes to
endosomes and an altered O-glycosylation of gel-forming mucins.
Also, these cells show a structurally abnormal Golgi apparatus,
consisting of fragmented and separate elements scattered around
the nucleus. The same unusual structures were observed in acidiﬁca-
tion-defective breast cancer cell lines. In these cells, both N and O
glycosylation were abnormal, as well as glycosylation of glycolipids
[126]. Thus, alterations in the pH in the Golgi may cause changes in
glycosylation in two ways: through the alteration of the localisation of
glycosyltransferases and through changes in their enzymatic activity.
Abnormal Golgi trafﬁcking is often paralleled by alterations of the
cisternal structures. No major alterations were observed in Golgi
morphology in skin ﬁbroblasts of patients with cutis laxa due to the
ATP6V0A2 defect. This is in accordance with experiments where V-
ATPase was inhibited speciﬁcally with baﬁlomycin A1 [125]. Delayed
retrograde translocation of Golgi membranes to the ER was observed
upon brefeldin A treatment, which indicates a disturbed Golgi-ER
retrograde transport. This mechanism has also been described in
patients with CDG due to a COG complex defect [127]. Therefore,
defective retrograde transport seems to be a general mechanism that
could result in abnormal N- and O-glycosylation, either directly or via
alterations in pH of acidic organels. Disruption of the interaction
between the a2-isoform and other proteins that regulate vesicular
trafﬁcking as described by Hurtado-Lorenzo et al. [50] may provide
another pathophysiological basis for defects in vesicular transport.
Functional defects of the elastic ﬁbre system lead to wrinkled skin
or cutis laxa. In the skin extracellular matrix (ECM), non-glycosylated
(e.g. elastin) and glycosylated proteins (e.g. the ﬁbulins, ﬁbronectin,
and collagen) have important functions in establishing and maintain-
ing elastic ﬁbres. The ﬁnal structure and adequate function of collagen
and elastin ﬁbres is dependent on the function and anchoring of these
essential matrix molecules. It can be speculated that either abnormal
glycosylation, other changes in post-translational processing or simply
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ATP6V0A2 mutations, leads to the cutis laxa phenotype. Reduced
glycosylation of ﬁbulin-5was shown to enhance binding of the protein
to tropoelastin and elastic ﬁbre formation in vitro [128]. Acute
treatment of cultured cells with several agents that disturb the pH
gradient in all cellular compartments was shown to severely reduce
tropoelastin secretion [129]. Although direct evidence for a role of the
a2 subunit in tropoelastin-containing secretory vesicles is missing, the
localisation in the Golgi compartment makes it likely that a2 directly
or indirectly inﬂuences the formation of Golgi-derived vesicles, either
for anterograde or retrograde transport.
In conclusion, patients presenting with an autosomal recessive
cutis laxa type II phenotype with a combined defect in N- and O-
glycosylation, have a mutation in the ATP6V0A2 gene. This gene
encodes the a2 subunit isoform of the vacuolar H+-ATPase. Defects in
pH regulation of acidic organels or vesicular transport within the cell
are hypothesized to be involved in the underlying pathomechanism.
Further investigations are necessary to elucidate the relation
between V-ATPase dysfunction, glycosylation defects and the cutis
laxa phenotype.
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